Cell News and Research

RSS

Stem Cell Culture Chip update to be presented at the World Stem Cell Summit

Fluidigm will provide the latest updates for its upcoming Stem Cell Culture Chip at the World Stem Cell Summit being held in Baltimore on September 21 – 23. This specialized integrated fluidic circuit will enable a variety of cell culture applications, including allowing stem cell researchers to simplify and automate protocols for turning differentiated cells into stem cells, and later fine tuning the reprogramming of those stem cells into targeted differentiated cells.

18 Sep 2009

80-unit patient housing facility for cancer patients and families

The SCCA House, an 80-unit patient housing facility for cancer patients and their families and caregivers, was dedicated today during ceremonies at its South Lake Union location. The facility is the second such "home away from home" building that is operated by the Seattle Cancer Care Alliance. Rooms are scheduled to be available to SCCA patients by the end of the month.

18 Sep 2009

Study reveals that low invadolysin could reduce fat storage in lipids

Researchers at the University of Edinburgh have found that the protein invadolysin, which is essential for healthy cell division, is present in lipid droplets - the parts of cells used to store fat.

18 Sep 2009

Griffin Securities' report features stem cell hypothesis of cancer

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has been featured in an in-depth report by Griffin Securities, a New York-based brokerage firm, highlighting the importance of the role that cancer stem cell (CSCs) targeting technology such as that employed by its lead product candidate, ICT-121, may play in developing future cancer treatments.

18 Sep 2009

Components of insulin-control system can reset body's biological clock

Many of the genes that regulate insulin also alter the timing of the circadian clock, a new study has found.

18 Sep 2009

Researchers link plasticity related gene-1 to lipid phosphates

In mice that are missing a protein found only in the brain, neural signals "go crazy," leaving the animals with epileptic seizures from a young age, researchers have found. The report in the September 18th Cell, a Cell Press publication, details what it is that happens when the protein encoded by plasticity related gene-1 (PRG-1) gets lost, revealing an important fine-tuning mechanism for brain function.

18 Sep 2009

Vitamin K prevents age-related conditions

An important analysis conducted by Children's Hospital Oakland Research Institute scientists suggests the importance of ensuring optimal dietary intakes of vitamin K to prevent age-related conditions such as bone fragility, arterial and kidney calcification, cardiovascular disease, and possibly cancer. Vitamin K is concentrated in dark green plants such as spinach or Swiss chard, and is either not present or present in only small amounts in most multivitamin pills.

18 Sep 2009

Insulin metabolism regulates body's internal clock

While scientists have known for several years that our body's internal clock helps regulate many biological processes, researchers have found that the reverse is also true: Many common biological processes - including insulin metabolism - regulate the clock, according to a new study by investigators at the University of Pennsylvania School of Medicine, the Genomics Institute of the Novartis Research Foundation, and the University of California at San Diego.

18 Sep 2009

Research reveals that iPSCs similar to embryonic stem cells

A team of researchers from the University of California, San Diego School of Medicine and the Salk Institute for Biological Studies in La Jolla have developed a safe strategy for reprogramming cells to a pluripotent state without use of viral vectors or genomic insertions. Their studies reveal that these induced pluripotent stem cells (iPSCs) are very similar to human embryonic stem cells, yet maintain a "transcriptional signature." In essence, these cells retain some memory of the donor cells they once were.

18 Sep 2009

New tool developed to provide precise and cost-effective data collection for drug discovery efforts

Cancer and cell biology experts at the University of Cincinnati (UC) have developed a new mass spectrometry-based tool they say provides more precise, cost-effective data collection for drug discovery efforts.

18 Sep 2009

GENova Biotherapeutics and Korean university sign strategic partnership agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a LOI for a strategic partnership agreement with the Hospital Medical Information Department of Suncheon Cheongam University in Seoul, South Korea to gain access to its ground-breaking cancer stem cell research information.

18 Sep 2009

PSC activation mechanisms help develop novel therapeutic approaches for pancreatic fibrosis

Fibrosis is a key feature of chronic pancreatitis and pancreatic cancer. The extensive deposition of extracellular matrix proteins fosters the development of an exocrine and endocrine organ insufficiency, and accelerates progression of the tumour. Pancreatic stellate cells (PSC) are the principal effector cells in pancreatic fibrosis. They are activated by profibrogenic mediators, which include, for example, cytokines and ethanol metabolites.

18 Sep 2009

Research reveals that reactive oxygen inhibition can limit cancer cell invasion

Researchers at the Burnham Institute for Medical Research (Burnham) have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis.

17 Sep 2009

Enzo expands its capability to perform simultaneous live-cell imaging of nuclear components

Enzo Life Sciences, a division of Enzo Biochem, Inc. (NYSE:ENZ), has added a novel new system to its CELLestial™ line of live cell analysis products, providing expanded capability to simultaneously image both the nucleus and the nucleolus in living cells, the Company announced today. Called the Total Nuclear-ID™ Green/Red Nucleolar/Nuclear Detection Kit, the new addition has been specifically optimized for demanding live cell microscopy applications.

17 Sep 2009

Second-quarter fiscal 2009 results announced by Gentium

Gentium S.p.A. (NASDAQ: GENT) today reported financial results for the second quarter ended June 30, 2009.

17 Sep 2009

Protein aggregation is linked to many conformational diseases

Researchers at the Department of Biochemistry and Molecular Biology of Universitat Autònoma de Barcelona (UAB) have revealed the process by which proteins with a tendency to cause conformational diseases such as amyotrophic lateral sclerosis, familial amyloidotic polyneuropathy, familial amyloidotic cardiomyopathy, etc. finally end up causing them.

17 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

Study reveals that YAP can be used for the diagnosis of gastric carcinoma

A research team led by Professor Yan Xin, from The Fourth Laboratory of Cancer Institute in China measured the expression of YAP and survivin in normal gastric mucosa, precancerous lesions and gastric carcinoma using an immunohistochemical method to analyze the significance and correlations of the 2 factors with gastric carcinogenesis.

17 Sep 2009

Discovery of key molecule may yield new therapies for AIDS and cancer

Discovery by Hebrew University of Jerusalem researchers of an additional role for a key molecule in our bodies provides a further step in world-wide efforts to develop genetic regulation aimed at controlling many diseases, including AIDS and various types of cancers.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009